Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22390599 | 0.79 | PARP10 (0.43) | FFAR4ACACB | |
| SCHEMBL31345398 | 0.79 | FFAR4 (0.51) | PTGS1PTGS2FFAR4ACACBMTNR1B | |
| SCHEMBL31345444 | 0.79 | FFAR4 (0.42) | PTGS1PTGS2FFAR4ACACBMTNR1B | |
| SCHEMBL23841515 | 0.79 | NQO1 (0.43) | PTGS2FFAR4GAA | |
| SCHEMBL23841532 | 0.78 | GAA (0.53) | MTNR1BGAA | |
| SCHEMBL18867917 | 0.78 | GAA (0.53) | MTNR1BGAA | |
| SCHEMBL6565551 | 0.76 | PTGS1 (0.48) | PTGS1PTGS2FFAR4HRH3APP | |
| SCHEMBL17125204 | 0.76 | PTGS1 (0.50) | PTGS1PTGS2FFAR4ACACBHRH3 | |
| SCHEMBL17449711 | 0.74 | PDE2A (0.44) | FFAR4 | |
| SCHEMBL24716435 | 0.74 | PTGS1 (0.46) | PTGS1PTGS2FFAR4ACACBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163454-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163454-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | CCR8, RPS8, HDHD5 | PTGS1 4394/4885PTGS2 4452/4885FFAR4 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.